

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **November 25, 2009**

Enzo Biochem, Inc.

(Exact Name of Registrant as Specified in Its Charter)

New York

(State or Other Jurisdiction of Incorporation)

001-09974

(Commission File Number)

13-2866202

(IRS Employer Identification No.)

**527 Madison Avenue
New York, New York**

(Address of Principal Executive Offices)

10022

(Zip Code)

(212) 583-0100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 25, 2009, the Board of Directors (the "Board") of Enzo Biochem, Inc. (the "Company") approved the termination of Mr. Shahram K. Rabbani's services as Secretary and Treasurer, respectively, of the Company, effective immediately. Mr. Rabbani will continue at this time to serve as a Director of the Company until his successor is duly elected and qualified.

Also on November 25, 2009, the Board appointed Dr. Elazar Rabbani to serve as Secretary of the Company, effective immediately. Dr. Rabbani (age 66) is a co-founder of the Company and has served as the Company's Chairman of the Board of Directors and Chief Executive Officer since its inception in 1976.

Also on November 25, 2009, the Board appointed Mr. Barry Weiner to serve as Treasurer of the Company, effective immediately. Mr. Weiner (age 59) is a co-founder of the Company. He has served as the Company's President since 1996 and is the Company's Chief Financial Officer and Principal Accounting Officer. Mr. Weiner previously held the position of Executive Vice President of the Company. Before his employment with the Company, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a Director of the New York Biotechnology Association.

Dr. Elazar Rabbani and Mr. Shahram K. Rabbani are brothers and Mr. Barry Weiner is their brother-in-law.

Item 7.01. Regulation FD Disclosure.

On November 25, 2009, the Company issued a press release announcing the termination of Mr. Shahram K. Rabbani as Secretary and Treasurer, respectively, of the Company and the appointments of Dr. Elazar Rabbani and Mr. Barry Weiner to serve as Secretary and Treasurer, respectively, as set forth in Item 5.02 of this Current Report on Form 8-K (this "Form 8-K"). A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1. This Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any generally incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
--------------------	--------------------

99.1	Press Release of Enzo Biochem, Inc., dated November 25, 2009.
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: November 25, 2009

By: /s/ Elazar Rabbani
Elazar Rabbani, Ph.D.
Enzo Biochem, Inc.
Chairman of the Board, Secretary and
Chief Executive Officer

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press Release of Enzo Biochem, Inc., dated November 25, 2009.



*news
release*

Enzo Biochem, Inc.
527 Madison Avenue
New York, NY 10022

FOR IMMEDIATE RELEASE

**ENZO BIOCHEM, INC. ANNOUNCES DEPARTURE
OF ITS SECRETARY AND TREASURER**

NEW YORK, NY, November 25, 2009 — Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Board of Directors approved the termination of Shahram K. Rabbani's services as the Company's Secretary and Treasurer, respectively, effective immediately. At this time, Mr. Rabbani will continue to serve as a Director of the Company.

The Company also announced today that its Board of Directors approved the appointment of Dr. Elazar Rabbani to serve as Secretary and the appointment of Barry W. Weiner to serve as Treasurer, effective immediately. Dr. Elazar Rabbani is the Company's current Chairman of the Board and Chief Executive Officer and Mr. Barry Weiner currently serves as the current President, Chief Financial Officer, Principal Accounting Officer and as a member of the Board of Directors of the Company.

About Enzo

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of both routine and esoteric test services to the medical community. Since its founding in 1976, the Company's strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene expression analysis, nucleic acid detection, protein biochemistry, and cellular analysis, among others. Its catalog of over **40,000** products serve the molecular biology, cellular biochemistry, drug discovery and pathology research markets worldwide. Enzo Clinical Labs division provides laboratory services for a growing roster of physicians in the New York Metropolitan area, as well as New Jersey and parts of Pennsylvania. Its tests include, in addition to routine tests, capabilities for detecting molecular infectious disease, molecular oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical diagnostic services that allows Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It has focused its efforts on developing treatment regimens for diseases and conditions for which

current treatment options are ineffective, costly, and/or cause unwanted side effects. In the course of the company's research and development activities, Enzo has developed a substantial portfolio of intellectual property assets, with over 240 issued patents worldwide and more than 200 pending patent applications.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

Contact:

For: Enzo Biochem, Inc.

Steven Anreder, 212-532-3232 or Michael Wachs, CEOcast, Inc., 212-732-4300
